Adaptive design study of LCQ908 in obesity and mixed dyslipidaemia

• Research type

  Research Study

• Full title

  A Phase 2 12-week multi-centre, randomised, double-blind, placebo-controlled, parallel-group adaptive design study to evaluate the safety and efficacy of LCQ908 for weight reduction and reduced LDL cholesterol in patients with obesity and mixed dyslipidaemia. (CLCQ908A2204).

• IRAS ID

  19015

• Contact name

  Nicola Lister

• Contact email

  nicola.lister@novartis.com

• Sponsor organisation

  Novartis Pharma AG

• Eudract number

  2009-010198-19

• ISRCTN Number

  N/A

• Research summary

  Research Summary not published at request of researcher

• REC name

  London - Harrow Research Ethics Committee

• REC reference

  09/H0709/29

• Date of REC Opinion

  21 May 2009

• REC opinion

  Further Information Favourable Opinion